BLASUBCUTANEOUSINJECTABLE4 Generics Approved
Approved
Jun 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
XGEVA (denosumab) by Amgen is rank ligand blocking activity [moa]. Approved for osteoporosis, bone metastases, multiple myeloma and 1 more indications. First approved in 2010.
XGEVA (denosumab) is a monoclonal antibody that blocks RANK ligand, a key mediator of osteoclast activation and bone resorption. Approved by the FDA in June 2010, it is indicated for preventing skeletal-related events in patients with bone metastases from solid tumors. The drug represents a novel mechanism class within oncology supportive care, offering an alternative to bisphosphonates for bone protection in advanced cancer patients.
$0.0BPart D
Mechanism of Action
RANK Ligand Blocking Activity
Pharmacologic Class:
RANK Ligand Inhibitor
Indications (4)
Worked on XGEVA at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.